1-20 of 23
Robert J. Kreitman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity

Robert J. Kreitman, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Kevin C. Conlon, Seth M. Steinberg, Wyndham Wilson, Thomas A. Waldmann, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 310–318.
https://doi.org/10.1158/1078-0432.CCR-15-1412
Published: 14 January 2016
View articletitled, Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity
Open the PDF for Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity in another window
Journal Articles

Minimal residual disease in hairy cell leukemia patients treated by BL22

Eugeny Arons, Joel Sunshine, Tara Suntum, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A51.
Published: 15 August 2014
View articletitled, Minimal residual disease in hairy cell leukemia patients treated by BL22
Journal Articles

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia

Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, Maryalice Stetler-Stevenson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6873–6881.
https://doi.org/10.1158/1078-0432.CCR-13-1752
Published: 16 December 2013
View articletitled, Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Open the PDF for Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia in another window
Journal Articles

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia

Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6313–6321.
https://doi.org/10.1158/1078-0432.CCR-13-1848
Published: 14 November 2013
View articletitled, Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Open the PDF for Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia in another window
Journal Articles

Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy

Rajat Singh, Yujian Zhang, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 152–160.
https://doi.org/10.1158/1078-0432.CCR-11-1839
Published: 02 January 2012
View articletitled, Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Open the PDF for Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy in another window
Journal Articles

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6398–6405.
https://doi.org/10.1158/1078-0432.CCR-11-0487
Published: 14 October 2011
View articletitled, Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Open the PDF for Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox in another window
Journal Articles

Thrombotic Microangiopathy with Targeted Cancer Agents

John A. Blake-Haskins, Robert J. Lechleider, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 5858–5866.
https://doi.org/10.1158/1078-0432.CCR-11-0804
Published: 14 September 2011
View articletitled, Thrombotic Microangiopathy with Targeted Cancer Agents
Open the PDF for Thrombotic Microangiopathy with Targeted Cancer Agents in another window
Journal Articles

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Alan S. Wayne, Robert J. Kreitman, Harry W. Findley, Glen Lew, Cynthia Delbrook, Seth M. Steinberg, Maryalice Stetler-Stevenson, David J. FitzGerald, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1894–1903.
https://doi.org/10.1158/1078-0432.CCR-09-2980
Published: 14 March 2010
View articletitled, Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Open the PDF for Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial in another window
Journal Articles

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

Robert J. Kreitman, Raffit Hassan, David J. FitzGerald, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5274–5279.
https://doi.org/10.1158/1078-0432.CCR-09-0062
Published: 12 August 2009
View articletitled, Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Open the PDF for Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P in another window
Journal Articles

CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

Ralph F. Alderson, Robert J. Kreitman, Tianling Chen, Peter Yeung, Ronald Herbst, Judy A. Fox, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 832–839.
https://doi.org/10.1158/1078-0432.CCR-08-1456
Published: 02 February 2009
View articletitled, CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Open the PDF for CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies in another window
Journal Articles

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar, Robert J. Kreitman, Hedy Kindler, Mark C. Willingham, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (17): 5144–5149.
https://doi.org/10.1158/1078-0432.CCR-07-0869
Published: 04 September 2007
View articletitled, Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Open the PDF for Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers in another window
Journal Articles

Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction

Evgeny Arons, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-05-2315
Published: 04 May 2006
View articletitled, Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction
Open the PDF for Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction in another window
Journal Articles

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Masanori Onda, Mark Willingham, Satoshi Nagata, Tapan K. Bera, Richard Beers, Mitchell Ho, Raffit Hassan, Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5840–5846.
https://doi.org/10.1158/1078-0432.CCR-05-0578
Published: 22 August 2005
View articletitled, New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA
Open the PDF for New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA in another window
Journal Articles

HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

SookHee Bang, Satoshi Nagata, Masanori Onda, Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (4): 1545–1550.
https://doi.org/10.1158/1078-0432.CCR-04-1939
Published: 02 March 2005
View articletitled, HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity
Open the PDF for HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity in another window
Journal Articles

Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies

Tomoko Ise, Hiroshi Maeda, Kenneth Santora, Laiman Xiang, Robert J. Kreitman, Ira Pastan, Satoshi Nagata
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 87–96.
https://doi.org/10.1158/1078-0432.87.11.1
Published: 21 January 2005
View articletitled, Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies
Open the PDF for Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies in another window
Journal Articles

Multidrug-Resistant Tumor Cells Remain Sensitive to a Recombinant Interleukin-4- Pseudomonas Exotoxin, Except When Overexpressing the Multidrug Resistance Protein MRP1

Mariska C. de Jong, George L. Scheffer, Henk J. Broxterman, Jan H. Hooijberg, Jerry W. Slootstra, Rob H. Meloen, Robert J. Kreitman, Syed R. Husain, Bharat H. Joshi, Raj K. Puri, Rik J. Scheper
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 5009–5017.
Published: 27 October 2003
View articletitled, Multidrug-Resistant Tumor Cells Remain Sensitive to a Recombinant Interleukin-4- Pseudomonas Exotoxin, Except When Overexpressing the Multidrug Resistance Protein MRP1
Open the PDF for Multidrug-Resistant Tumor Cells Remain Sensitive to a Recombinant Interleukin-4- Pseudomonas Exotoxin, Except When Overexpressing the Multidrug Resistance Protein MRP1 in another window
Journal Articles

Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments

Satoshi Nagata, Masanori Onda, Yoshito Numata, Kenneth Santora, Richard Beers, Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2345–2355.
Published: 01 July 2002
View articletitled, Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments
Open the PDF for Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments in another window
Journal Articles

Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia

Arthur E. Frankel, Bayard L. Powell, Philip D. Hall, L. Douglas Case, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 1004–1013.
Published: 01 May 2002
View articletitled, Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia
Open the PDF for Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia in another window
Journal Articles

Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display

Giuliana Salvatore, Richard Beers, Inger Margulies, Robert J. Kreitman, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 995–1002.
Published: 01 April 2002
View articletitled, Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
Open the PDF for Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display in another window
Journal Articles

Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma

Robert W. Rand, Robert J. Kreitman, Nicholas Patronas, Frederick Varricchio, Ira Pastan, Raj K. Puri
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2157–2165.
Published: 01 June 2000
View articletitled, Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma
Open the PDF for Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma in another window